Literature DB >> 27881875

Loss of p300 accelerates MDS-associated leukemogenesis.

G Cheng1, F Liu1, T Asai1, F Lai2, N Man1, H Xu3, S Chen1, S Greenblatt1, P-J Hamard1, K Ando1, X Chen4, L Wang1, C Martinez1, M Tadi1, L Wang1, M Xu1, F-C Yang1, R Shiekhattar2, S D Nimer1,5.   

Abstract

The role that changes in DNA methylation and histone modifications have in human malignancies is poorly understood. p300 and CREB-binding protein (CBP), two distinct but highly homologous lysine acetyltransferases, are mutated in several cancers, suggesting their role as tumor suppressors. In the current study, we found that deletion of p300, but not CBP, markedly accelerated the leukemogenesis ofNup98-HoxD13 (NHD13) transgenic mice, an animal model that phenotypically copies human myelodysplastic syndrome (MDS). p300 deletion restored the ability of NHD13 expressing hematopoietic stem and progenitor cells (HSPCs) to self-renew in vitro, and to expand in vivo, with an increase in stem cell symmetric self-renewal divisions and a decrease in apoptosis. Furthermore, loss of p300, but not CBP, promoted cytokine signaling, including enhanced activation of the MAPK and JAK/STAT pathways in the HSPC compartment. Altogether, our data indicate that p300 has a pivotal role in blocking the transformation of MDS to acute myeloid leukemia, a role distinct from that of CBP.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27881875      PMCID: PMC5667352          DOI: 10.1038/leu.2016.347

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  36 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  CBP/p300 in cell growth, transformation, and development.

Authors:  R H Goodman; S Smolik
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

Review 3.  Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

Authors:  Lynda A O'Sullivan; Clifford Liongue; Rowena S Lewis; Sarah E M Stephenson; Alister C Ward
Journal:  Mol Immunol       Date:  2007-01-17       Impact factor: 4.407

4.  Imaging hematopoietic precursor division in real time.

Authors:  Mingfu Wu; Hyog Young Kwon; Frederique Rattis; Jordan Blum; Chen Zhao; Rina Ashkenazi; Trachette L Jackson; Nicholas Gaiano; Tim Oliver; Tannishtha Reya
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

5.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model.

Authors:  Haiming Xu; Silvia Menendez; Brigitte Schlegelberger; Narae Bae; Peter D Aplan; Gudrun Göhring; Tony R Deblasio; Stephen D Nimer
Journal:  Blood       Date:  2012-08-27       Impact factor: 22.113

8.  Age-related epigenetic drift in the pathogenesis of MDS and AML.

Authors:  Shinji Maegawa; Sheryl M Gough; Naoko Watanabe-Okochi; Yue Lu; Nianxiang Zhang; Ryan J Castoro; Marcos R H Estecio; Jaroslav Jelinek; Shoudan Liang; Toshio Kitamura; Peter D Aplan; Jean-Pierre J Issa
Journal:  Genome Res       Date:  2014-01-10       Impact factor: 9.043

9.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

10.  Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Authors:  Fernando Ramos; Cristina Robledo; Francisco Miguel Izquierdo-García; Dimas Suárez-Vilela; Rocío Benito; Marta Fuertes; Andrés Insunza; Eva Barragán; Mónica Del Rey; José María García-Ruiz de Morales; Mar Tormo; Eduardo Salido; Lurdes Zamora; Carmen Pedro; Javier Sánchez-Del-Real; María Díez-Campelo; Consuelo Del Cañizo; Guillermo F Sanz; Jesús María Hernández-Rivas
Journal:  Oncotarget       Date:  2016-05-24
View more
  18 in total

Review 1.  Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.

Authors:  Qingjuan Chen; Binhui Yang; Xiaochen Liu; Xu D Zhang; Lirong Zhang; Tao Liu
Journal:  Theranostics       Date:  2022-06-21       Impact factor: 11.600

2.  Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells.

Authors:  Xiangguo Shi; Ayumi Kitano; Yajian Jiang; Victor Luu; Kevin A Hoegenauer; Daisuke Nakada
Journal:  Exp Hematol       Date:  2018-05-08       Impact factor: 3.084

Review 3.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

4.  Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.

Authors:  Sumiko Takao; Lauren Forbes; Masahiro Uni; Shuyuan Cheng; Jose Mario Bello Pineda; Yusuke Tarumoto; Paolo Cifani; Gerard Minuesa; Celine Chen; Michael G Kharas; Robert K Bradley; Christopher R Vakoc; Richard P Koche; Alex Kentsis
Journal:  Elife       Date:  2021-02-02       Impact factor: 8.713

5.  Peptidomimetic blockade of MYB in acute myeloid leukemia.

Authors:  Kavitha Ramaswamy; Lauren Forbes; Gerard Minuesa; Tatyana Gindin; Fiona Brown; Michael G Kharas; Andrei V Krivtsov; Scott A Armstrong; Eric Still; Elisa de Stanchina; Birgit Knoechel; Richard Koche; Alex Kentsis
Journal:  Nat Commun       Date:  2018-01-09       Impact factor: 14.919

6.  Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes.

Authors:  Huijuan Jiang; Ningbo Cui; Liyan Yang; Chunyan Liu; Lanzhu Yue; Lifang Guo; Huaquan Wang; Zonghong Shao
Journal:  Oncotarget       Date:  2017-10-06

Review 7.  MYC-Master Regulator of the Cancer Epigenome and Transcriptome.

Authors:  Candace J Poole; Jan van Riggelen
Journal:  Genes (Basel)       Date:  2017-05-13       Impact factor: 4.096

8.  Unscheduled HDAC4 repressive activity in human fibroblasts triggers TP53-dependent senescence and favors cell transformation.

Authors:  Harikrishnareddy Paluvai; Eros Di Giorgio; Claudio Brancolini
Journal:  Mol Oncol       Date:  2018-11-14       Impact factor: 6.603

Review 9.  Recent advances in the understanding and treatment of acute myeloid leukemia.

Authors:  Justin Watts; Stephen Nimer
Journal:  F1000Res       Date:  2018-08-06

10.  SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.

Authors:  Bing-Yi Chen; Junhong Song; Cheng-Long Hu; Shu-Bei Chen; Qunling Zhang; Chun-Hui Xu; Ji-Chuan Wu; Dan Hou; Ming Sun; Yuan-Liang Zhang; Na Liu; Peng-Cheng Yu; Ping Liu; Li-Juan Zong; Jia-Ying Zhang; Ruo-Fei Dai; Fei Lan; Qiu-Hua Huang; Su-Jiang Zhang; Stephen D Nimer; Zhu Chen; Sai-Juan Chen; Xiao-Jian Sun; Lan Wang
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.